FDA committee recommends approval of alefacept (Amevive) for treatmentof psoriasis

Silver Spring, Md. - The FDA Dermatologic and OphthalmicAdvisory Committee on May 23 strongly recommended approval of alefacept,a systemic drug for the treatment of chronic plaque psoriasis.

Related Videos
Related Content

Vitamin D Supplements During Pregnancy My Reduce Eczema in Infants

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Lauren Miller, PA-C, Discusses SDPA and Updates in Dermatology

March 23rd 2023

Vitamin D Supplements During Pregnancy My Reduce Eczema in Infants

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Lauren Miller, PA-C, Discusses SDPA and Updates in Dermatology

March 23rd 2023

Vitamin D Supplements During Pregnancy My Reduce Eczema in Infants

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Lauren Miller, PA-C, Discusses SDPA and Updates in Dermatology

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.